Compositions and Methods of Treating Muscle Dystrophy
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 63/001,211, filed Mar 27, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,446,387 | Compositions and Methods of Treating Muscle Dystrophy In force · High confidence | Avidity Biosciences, Inc. | In force | High confidence | ||
| US 11,707,532 | Compositions and Methods of Treating Muscle Dystrophy In force · High confidence | Avidity Biosciences, Inc. | In force | High confidence | ||
| US 12,427,202 | Compositions and Methods of Treating Muscle Dystrophy In force · High confidence | Avidity Biosciences, Inc. | In force | High confidence | ||
| US 12,648,999 | Compositions and Methods of Treating Muscle Dystrophy In force · High confidence | Avidity Biosciences, Inc. | In force | High confidence | ||
| Application 19/263,372 | Compositions and Methods of Treating Muscle Dystrophy Pending Not granted | Avidity Biosciences, Inc. | Pending | Not granted | ||
| Application 19/668,501 | Compositions and Methods of Treating Muscle Dystrophy Pending Not granted | Avidity Biosciences, Inc. | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Avidity Biosciences, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.